Intellia Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| INTELLIA THERAPEUTICS, INC. | |
|---|---|
| By: | /s/ John M. Leonard |
| John M. Leonard, M.D. | |
| President and Chief Executive Officer | |
Dated: February 22, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ John M. Leonard | President, Chief Executive Officer and Director | February 22, 2024 |
| John M. Leonard, M.D. | (Principal Executive Officer) | |
| /s/ Glenn Goddard | Executive Vice President, Chief Financial Officer | February 22, 2024 |
| Glenn Goddard | (Principal Financial and Accounting Officer) | |
| /s/ Muna Bhanji | Director | February 22, 2024 |
| Muna Bhanji | ||
| /s/ Bill Chase | Director | February 22, 2024 |
| Bill Chase | ||
| /s/ Fred Cohen | Director | February 22, 2024 |
| Fred Cohen, M.D. | ||
| /s/ Jesse Goodman | Director | February 22, 2024 |
| Jesse Goodman, M.D. | ||
| /s/ Georgia Keresty | Director | February 22, 2024 |
| Georgia Keresty | ||
| /s/ Frank Verwiel | Director | February 22, 2024 |
|---|---|---|
| Frank Verwiel, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.